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Synthesizing efficacious genistein in
conjugation with superparamagnetic Fe3O4
decorated with bio-compatible
carboxymethylated chitosan against acute
leukemia lymphoma
Rachel Ghasemi Goorbandi1,2, Mohammad Reza Mohammadi4 and Kianoosh Malekzadeh2,3*
Abstract
Background: Genistein (C15H10O5) is a soy isoflavone with anti-cancer properties such as inhibition of cell growth,
proliferation and tumor invasion, but effective dosage against hematopoietic malignant cells was not in non-toxic
range. This property cause to impede its usage as chemotherapeutic agent. Therefore, this hypothesis raised that
synthesizing biocompatible nanoparticle could assist to prevail this struggle.
Methods: Genistein covalently attached on Fe3O4 nanoparticles decorated with carboxymethylated chitosan to
fabricate Fe3O4-CMC-genistein in alkaline circumstance. This obtained nanoparticles were evaluated by TEM, DLS,
FTIR, XRD and VSM and its anti-cancer effect by growth rate and MTT assays as well as flow cytometer on ALL
cancer cell lines.
Results: Different evaluations indicated that the drug delivery vehicle had a mean diameter size around 12ƞm with
well bounded components. This system presented high degree of magnetization and superparamagnetic
properties as well as good water solubility. In comparison with pure genistein, significant growth inhibition on
hematopoietic cancer cells in lower dose of genistein nano-conjugated onto Fe3O4-CMC. It increased long lasting
effect of genistein in cancer cells also.
Conclusion: This delivery system for genistein could be remarkably promised and futuristic as biocompatible
chemotherapeutic agent against hematopoietic malignant cells.
Keywords: Acute leukemia lymphoma (ALL), Chitosan, Genistein, Superparamagnetic Fe3O4, Nano particle delivery
system
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Introduction
Nanoparticles are used in management of different can-
cers through active development for in vivo imaging for
cancers, detection of tumor cells biomarkers, and usage
in targeted drug delivery [1].
Magnetic nanoparticles (MNPs) are widely used for
therapeutic and diagnostic objectives, because different
polymer can be loaded on these materials. Another point
is their ease of preparation and strong magnetic proper-
ties, which make it possible to apply them for targeted
drug delivery [2]. These magnetic particles are also used
for cell label and separation, immunoassay, imaging, and
targeted drug delivery [3]. Targeting of specific tissues is
possible by using magnetic nanoparticles due to their high
magnetization value, water dispersion. These improve
their non-toxic properties and biocompatibility [4].
Magnetic gene and drug delivery is one of the most
important applications of iron oxide nanoparticles [5].
Superparamagnetic Iron Oxide Nanoparticles (SPIONs)
are iron nanoparticles, which are widely used because of
their biocompatibility and their ease of synthesis [6].
Magnetite (Fe3O4) and maghemite (γFe2O3) are the most
commonly studied iron oxide particles.
For Surface stabilization of the magnetic nano-particles
(MNPs), the magnetic core must be covered with organic
materials and targeting ligands. As magnetic nanoparticles
tend to aggregate because of their high surface energy, by
using this technique, the surface of the particles will be
prevented from oxidation and provide a site for linkage of
drug molecules or gene vectors [5]. The core size of
SPIONs ranges from 10ηm to 100ηm which makes is pos-
sible to use them in targeted drug delivery and other ap-
plications in biomedical sciences. These iron NPs can be
coated by different organic and inorganic materials, which
can be guided to the target tissues by their magnetic prop-
erties. Absence of magnetic properties after removal of ex-
ternal magnetic field avoids their agglomeration. By this
mechanism, they remain in circulation and vessel embol-
ism, therefore thrombosis is prevented [7].
Chitosan is derived from chitin (a natural polysaccharide),
which is a carbohydrate found in crustaceans exoskeleton.
Three different chitosan derivatives are obtained by its car-
boxymethylation including O-carboxymethyl chitosan, N-
carboxymethyl chitosan, and N, O-carboxymethyl chitosan
[8]. O-carboxymethyl chitosan (OCMCS) is widely applied
in biomedical applications because of its blood compatibil-
ity properties [9]. One of the important activities of chito-
san is antioxidant activity because of its activity against
superoxide anion. The antioxidant activity of chitosan is
used in pharmacy for production of extended-release tablet
with high antioxidant activity [10]. Although chitosan is re-
ported to induce apoptosis, but carboxymethylated chitosan
(CMC) can inhibit apoptosis. It seems that it is related to
the protection of mitochondrial function and decreasing
nitric oxide and reactive oxygen species level [11]. Chitosan
has also been known as low toxicity chemotherapeutic ma-
terial, but its use is limited because of specific properties
such as poor solubility in pH upper than 6.5. Chitosan is
soluble only in pH < 6.5 due to strong hydrogen bands
which cause stable crystalline structure. To achieve the best
results and to overcome these limitations, carboxymethy-
lated chitosan, which is soluble in alkaline and acidic aque-
ous solutions [8], can be attached to Fe3O4 nanoparticles to
be used in drug delivery systems [12]. Different molecules
and antibodies can be loaded into Fe3O4-CMC nanoparti-
cles. In the other hand, its amphiphilic properties are help-
ful for its usage in biomedical researches [13].
Genistein (C15H10O5) is a soy isoflavone, which is inter-
ested for its anti-cancer activities and can be considered in
chemotherapy [14–16] Different mechanisms of action are
reported for genistein. One possible mechanism is inhib-
ition of topoisomerase II, which decreases cell proliferation
[17]. It was observed that genistein can inhibit of tumor
cells in gastric, breast, lung, prostate, pancreatic, liver,
ovarian, colon, and bladder cancer [15, 16]. Genistein not
only prevents tumor cell growth, invasion, and metastasis
but also increases tumor cells sensitivity to chemotherapy.
Several studies have tried to reveal possible mechanisms of
action of genistein in gastric cancer [17–19].
In gastric cancer, genistein decreases Gli1 gene expres-
sion and attenuates cancer stem-like properties. By this
mechanism, genistein prevents invasion of tumor cells and
inhibits tumor growth and metastasis [17]. Genistein also
reduces gastric cancer chemo-resistance [18]. Another
mechanism is increase in tumor suppression PTEN ex-
pression [20]. In addition to above studies, some cohort
studies have reported the decrease risk of gastric cancer
with isoflavones consumption [21].
As the anti-cancer feature of genistein has already been
noticed as candidate herbal chemotherapeutic agent in
different cancer but its effect in that growth inhibition was
linearly related to genistein concentration. Carlo-Stella
et al., (1996) revealed that (i) genistein strongly inhibits
the growth of normal and leukaemic haemopoietic pro-
genitors; (ii) growth inhibition is dose- and time-
dependent; (iii) leukaemic progenitors are more sensitive
than normal progenitors to genistein-induced growth in-
hibition [22]. This project was conducted to investigate
whether anti-carcinogenic effects of genistein can be im-
proved by using magnetic nanoparticles composed of a
magnetic core and a biocompatible polymeric shell and
genistein molecule in lower dose on hematopoietic cancer
cell line, which leads to development of a promising car-
rier and targeting anticancer therapy.
Material and methods
The required materials were Iron (II) chloride tetrahydrate
(99%), iron (III) chloride hexahydrate (98%), ammonia
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solution 25% GR for analysis, (Merck, Germany)(3-
Dimethylaminopropyl)-3-ethylcarbodiimide (97%), Chito-
san with molecular weight of 600,000–800,000 (Acros
Organices) Monochloroacetic acid, synthetic Genistein
(99%), NHS (N-Hydroxysuccinimide), DMSO (Dimethyl
sulphoxide), MTT (Thiazolyl Blue Tetrazolium Bromide),
Annexin V-FITC Apoptosis Detection Kit (Sigma Al-
drich), FBS (Fetal bovine serum), Penstrep (Penicillin
/Streptomycin), RPMI-1640, PI (Propidium Iodide Solu-
tion) (GIBCO). MOLT-4 cell lines were purchased from
Pasteur Institute of Iran.
Synthesis of superparamagnetic Iron oxide nanoparticles
Magnetite nanoparticles were synthesized by coprecipi-
tating iron (II) chloride and iron (III) chloride in alkaline
solution. First 1.2 g of ferric chloride dissolved in 60ml
distilled water and ferrous solution prepared by dissolv-
ing 0.6 g of ferrous chloride in 30ml of distilled water.
After mixing of the solutions in a three neck flasks with
magnetic stirring and purging the nitrogen gas for 10
min, 4 ml of 25% (w/w) NH3·H2O was added drop wise
into the mixture solution and the pH of the solution was
carefully monitored in order to reach 11.0. Change the
color of the solution to dark black, showing formation of
Fe3O4 and SPION precipitation. The black precipitate
was separated from the solution with a neodymium
magnet and rinsed several times with distilled water and
ethanol and the pH value descended to 7.0. Resulted
SPION dried in a vacuum oven in 70 °C for 4 h [23].
Fe2þ þ 2Fe3þ þ 8OH−→Fe3O4↓þ 4H2O
Synthesis of carboxymethyl chitosan
For synthesis of O-carboxymethyl chitosan, 3 g chitosan
was immersed in 25 ml of 50% wt NaOH solution to
swell and alkalize for 24 h at room temperature. The
alkalized chitosan was filtered using a G2 sintered fun-
nel. The solution of 5 g of monochloroacetic acid in 25
ml of isopropanol added drop-wise on it for 30 min.
After 4 h reaction at 60 °C temperature, the solvent was
removed by filtering the mixture. The obtained product
was dissolved in 100 ml of distilled water and 2.5 M HCl
was used to adjust the pH to 7.0. Then this solution was
filtered and carboxymethylated chitosan was precipitate
by adding 400 ml of anhydrous ethanol. The final prod-
uct was filtered, rinsed several times with ethanol and
vacuum-dried at room temperature.
Preparation of Fe3O4 bound carboxymethylated chitosan
For preparation of carboxymethyl chitosan coated iron
oxide nanoparticles, 28.25 μl of EDC (density 0.885 g/
cm3) was added to 4 ml of phosphate buffer (0.2 mol/L
Na2HPO4–NaH2PO4, pH 6.0), then 75 mg of Fe3O4
nanoparticles were added to the mixture and ultrasoni-
cated for 10 min. After that 25 mg of carboxymethyl chi-
tosan in 1ml phosphate buffer was added to the
obtained mixture and it was ultrasonicated for another
1 h. For distinction of the product from the mixture,
neodymium magnet was used. Finally the product was
washed with water and ethanol three times and
vacuumed dried at room temperature.
Immobilizing genistein onto the CMC modified Fe3O4
nanoparticles
The next step was immobilization of genistein onto chi-
tosan coated iron oxide nanoparticles. To reach this aim,
genistein (2.5 mg) EDC (5.65 μl), NHS (6 mg) were dis-
solved in 5ml of phosphate buffer (pH = 6.0, 2 mmol/L).
Then 10 mg of Fe3O4-CMC nanoparticles was added.
The suspension was then ultrasonicated for 10 min in
4 °C and shacked at room temperature for 24 h. Fe3O4-
CMC-genistein was recovered by magnet from the reac-
tion mixture. The precipitate was washed with 2 mM
phosphate buffer (pH 6.0) and vacuumed dried at room
temperature.
Characterization
Powder X-ray diffraction were recorded using a diffract-
ometer (XRD-STOE-Stidy-mp) in 25 °C using CuKα radi-
ation (λ = 1.54178 Å). Fourier transform infrared (FT-IR)
spectroscopy of the samples was performed on a Bruker-
Veator-22, FT-IR spectrophotometer for characterization
the surface reaction of samples over the range of 400–
4000 cm− 1.Morphology, mean particle size and size distri-
bution was performed using Zeiss-EM10C, transmission
electron microscopy (TEM), electron microscope operated
at 100 KV DLS analysis. Magnetic characteristics were
measured on a 7400 Lake shore vibrating sample magnet-
ometer (VSM) at room temperature.
Cell culture
MOLT-4, MOLT17 and Jurket cell lines purchased from
Pasteur Institute of Iran, centrifuged (130 g for 5 min)
and suspended in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS), 100 mg/mL streptomycine, and
100 U/mL penicillin then cultured in 6-well micro plates
(9.6 cm2) with concentration of 15 × 104 cells/ml and in-
cubated in a humidified incubator by standard cell cul-
ture conditions (37 °C and 5% CO2).
Proliferation and MTT studies
In order to conduction the inhibiting effect of nano-
conjugated Fe3O4-CMC-genistein in comparison with
genistein and un-treated cells, briefly, a density of 15 ×
104 /ml cells were seeded per each well of a six-well
plate. Cells were treated with only genistein, Fe3O4-
CMC nano-particles, and Fe3O4-CMC-genistein nano-
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conjugated with different doses from 20 and 40 μmol/L
and incubated at 37 °C and 5% CO2. Doses 20 and
40 μmol/L selected in base of the IC50 obtained from
MTT assay. After first 48 h, post treatment with 24 h’
interval were done for next remain 5 days. Hematocyt-
ometer was applied to count viable cells from three wells
per dose. The appearance of healthy looking, rounded
cells with intact cell membranes considered as viable
cells versus dead or dying cells with ghostly, necrotic ap-
pearances and disrupted cell membranes. Tryphan-blue
test was also performed.
Hematopoietic cancer cells were also treated with nano-
conjugated Fe3O4-CMC-genistein as well as naked genis-
tein in concentrations of 20, 40, 60, 80 and 100 μmol/L
and then viable cells counted at 24, 48 and 72 h. Percent
reduction of growth was calculated by dividing the num-
ber of treated cells with genistein or nano-conjugated
Fe3O4-CMC-genistein to number of untreated cells.
MTT assay was also performed to detect the effect of
Fe3O4-CMC-genistein nano-conjugate on proliferation of
hematopoietic cancer cells as compare to naked genistein.
Briefly, 20 μl MTT (5mg/ml) was added up to each well
of incubated cells with only genistein, Fe3O4-CMC nano-
particles, and Fe3O4-CMC-genistein nano-conjugated, and
then incubated for 4 h. Fe3O4-CMC nano-particles with-
out genistein used as control the cytotoxic effect of
nonao-particles. Then, the supernatants were removed
and proceed by adding of 200 μl DMSO to dissolve forma-
zen crystals. After 10min incubation, the plate was read at
490 nm by micro plate reader versus to non-treated cells.
Since, DMSO is solvent of genistein, and the final DMSO
concentration n the medium was lesser than 0.1%, there-
fore, the cells treated with only DMSO also analyzed as
control of cytotoxicity effect. Data of MTT assay was re-
peated 3 times for each cell line per dose.
Flow cytometry
Apoptosis particularly early apoptosis was also evaluated
by flow cytometry analysis. For this purpose,
hematopoietic cancer cells were cultured and treated
with only genistein, synthesized nanoparticles Fe3O4-
CMC without geneistein, and synthesized nano-
conjugated Fe3O4-CMC-genistein for 48 h. Then, ice-
cold PBS used to resuspend in 500 μL binding buffer
and then incubated for 25 min more in dark. After that,
solution of annexin-V and propidium iodide (PI) was
added to the cells and then 400 μl binding buffer was
added to each tube. FACS Calibur (BD; USA) instrument
was used for analyzing.
Statistical analysis
The data were analyzed using Excel 2010, Graph Pad
Prism 5.0 and SPSS softwares. Comparison of growth
rate, apoptosis of cancer cell line between non-treated
and treated, and nano-conjugated and naked genistein in
different doses were performed by the non-parametric
test followed by Mann-Whitney test and p-values < 0.05
were considered as statistically significant. Figure 1
shows a schematic illustration of synthesis methods and
cell treatment.
Results
Particle size and morphology of Fe3O4 and Fe3O4-CMC-
genistein nanoparticles
For confirmation of the size and morphology of Fe3O4-
nanoparticles and the Fe3O4-CMC-genistein samples,
transmission electron microscopy (TEM) was used. As
shown in Fig. 2, the iron oxide nanoparticles and Fe3O4-
CMC-genistein particles had spherical shape and were
distanced from each other and tend to aggregate.
The size of nanoparticles (NPs) was assessed by dy-
namic light scattering (DLS). Iron oxide MNPs have
various size of between 7 to 14 nm. Figure 3 indicated
that the Fe3O4 nanoparticles exhibit a narrow size distri-
bution and the mean diameter of these particles is calcu-
lated around 10 nm. After conjugation of Fe3O4-CMC
with genistein, the size of nanoparticles increased to 8 to
16 nm.
Crystallography and phase study
The pattern of X-ray diffraction of naked iron oxide
NPs, Fe3O4-CMC NPs and Fe3O4-CMC-genistein NPs
are shown in Fig. 4. Naked iron NPs show six intense
peaks between 30° and 70° at 30.3854°, 35.6762°,
43.3200°, 53.8317°, 57.4892°and 62.9182°, which are at-
tributed to (220), (311), (400), (422), (511), and (440). It
confirmed that the magnetite NPs were pure iron oxide
with a cubic inverse spinal structure by this method.
Pure iron oxide NPs crystallite size calculated by Debye-
Scherrer eq. (D = Kλ/βcosθ). In this equation, K is the
Debye-Scherrer constant (0.9), λ is the X-ray wavelength
(1.54178 nm), β is the peak width of half-maximum, and
θ is the diffraction angle [24]. The crystallite size was
about 8.8 nm.
The surface reactions
Fourier transform infrared spectroscopy (FTIR) and
spectra of Fe3O4 nanoparticles of CMC and Fe3O4-CMC
nanoparticles before conjugation with genistein and also
spectra of naked genistein and Fe3O4-CMC-genistein are
shown in Fig. 5. In this figure, intense and broad band in
the 3200–3600 cm− 1 of the spectrum of Fe3O4nanoparti-
cles confirms that NPs surface is covered with hydroxyl
groups. Also, the vibration band, which is seen in about
560–580 cm− 1 is characteristic band for naked iron
oxide NPs and is attributed to Fe-O group [25] (Fig. 5a).
The surface chemistry and the spectra of CMC
shows the characteristic band at around 3425 cm− 1
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Fig. 2 TEM micrographs of (a) Iron oxide nanoparticles (Fe3O4 NPs) and (b) Genistein conjugated Fe3O4-CMC nanoparticles
Fig. 1 Schematic illustration for synthesizing Fe3O4-CMCH-genistein nanoparticles
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corresponding to the O −H stretching and N-H
stretching vibrations. The peaks at 1637 cm− 1 and
1423 cm− 1 are related to the N–H bend vibration of
amines functional groups of CMC and symmetric
stretching vibration of COO, respectively (Fig. 5b). In
the spectra of Fe3O4-CMC nanoparticles, the main
absorption peaks are at 1629 cm− 1 and 1415 cm− 1
wave numbers. Descending of 1637 cm− 1 and 1423
cm− 1 to lower wave numbers of 1629 cm− 1 and 1415
cm− 1 can be related to the successful bonding be-
tween the hydroxyl groups of the Fe3O4 nanoparticles
and the carboxyl groups of CMC [26] (Fig. 5d). Fig-
ure 5e shows the spectra of Fe3O4-CMC-genistein
nanoparticles. The spectrum of the resulted Fe3O4-
CMC-genistein nano-conjugate shows the characteris-
tic bands of the original Fe3O4-CMC at 1629, 1415
cm− 1 and also characteristic peaks of genistein were
at 1407 and 1642 cm− 1 (Fig. 5c) confirming that
genistein is successfully conjugated onto the Fe3O4-
CMC nanoparticles.
Magnetic properties
The synthesized nanoparticles of genistein were analyzed
by using a vibrating sample magnetometer at room
temperature. The hysteresis loops for samples are shown
in Fig. 6. The saturation magnetization for the Fe3O4
and Fe3O4-CMC-genistein nanoparticles was 74.85 emu/
g and 59.60 emu/g respectively.
The large magnetic particles aggregate after exposure
to a magnetic field. Synthesizing smaller size nanoparti-
cles with high degree of magnetization can offer suitable
properties in biomedical applications, which is our aim
in this research work. As it can be seen in the Fig. 7,
particles can be easily separated from the solution in the
presence of magnetic field. Our samples show super-
paramagnetic behaviors. It demonstrated that magnetite
Fig. 3 The size and size distribution of (a) Iron oxide nanoparticles (Fe3O4 NPs) and (b) Genistein conjugated Fe3O4-CMC nanoparticles
according to DLS results
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nanoparticles were incorporated in the composite parti-
cles with no remanence effect from the hysteresis loops
when magnetic field applies.
Cell growth studies
The cell lines of acute lymphoblastic lymphoma (ALL)
were treated to naked genistein as well as synthesized
nano-conjugated Fe3O4-CMC-genisteinin. After a single
treatment at 72th hours with 25 μmol/L and 50 μmol/L
genistein as well as nano-conjugated genistein, viable
cells were counted for each 24 h intervals. Consequently,
7-days growth curves were obtained in order to evalu-
ation of long term survival rate (Fig. 8).
We observed that cell growth of these ALL cell lines
were reduced to as low as 31.0% compared with
genistein-treated cells in the effect of 20 μmol/L nano-
conjugated genistein. Abatement of cell growth around
34% was took place by 20 μmol/L genistein, whereas this
decreasing for 54% for 20 μmol/L nano-conjugated
Fe3O4-CMC-genistein, as comparison with non-treated
cells. The same trait was observed for higher concentra-
tion (40 μmol/L). Decreasing of cell growth by applying
40 μmol/L nano-conjugated Fe3O4-CMC-genistein was
33% lower than 50 μmol/L naked genistein. In spite of
higher effectiveness of 50 μmol/L nano-conjugated ge-
nistein in reduction of cell growth in comparison with
20 μmol/L nano-conjugated Fe3O4-CMC-genistein, but
there was no significant difference observed (p = 0.55).
Interestingly, the reduction of cancer cell growth in-
duced by 20 μmol/ Fe3O4-CMC-genistein nano-
conjugate was similar to 40 μmol/L genistein (Fig. 8). It
seems that nano-conjugation of genistein with Fe3O4-
CMC could avoid the usage of higher concentration of
genistein. It seems that nano-conjugation of genistein
can improve its chemotherapy against of ALL cancer
even in lower doses near to physiological serum level. It
expects to minimize side effects such as toxicity on nor-
mal cells.
We also treated hematopoietic cancer cells with con-
centrations of 20, 40, 60, 80 and 100 μmol/L of genistein
and Fe3O4-CMC-genistein nano-conjugation for 24, 48
and 72 h. The effect of genistein and its synthesized
nanoparticles on cell proliferation was also evaluated by
MTT assay. Obtained findings through MTT assay
Fig. 4 X-ray diffraction patterns for (a) Iron oxide nanoparticles (Fe3O4 NPs) and (b) Genistein conjugated Fe3O4-CMC nanoparticles
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indicated that both genistein and nano-conjugated
Fe3O4-CMC-genistein could significantly reduce prolif-
eration of cells (p < 0.001), but nano-conjugated genis-
tein totally showed higher inhibition rate in comparison
with genistein, especially in 72 h. Treatment of
hematopoietic cancer cells with nano-conjugated at
higher doses (80 and 100 μM) for 24 h had lower inhib-
ition effect than naked genistein. The inhibition effect of
genistein was even little better than the effect of nano-
conjugate genistein after 48 h of treatment. Reduction of
cell proliferation for 44% was observed by 72 h treatment
of nano-conjugated Fe3O4-CMC-genistein in compari-
son with naked genistein (Fig. 9). The prevention of cell
proliferation in effect of 10 to 80 μmol/L of nanoparti-
cles calculated from 34.0 to 71.6% in MTT assay after
72 h treatment.
Apoptosis analysis
The percentage of apoptosis has been analyzed by FACS
analysis in the effect of 48 h treatment with 20 and
Fig. 5 Fourier transform infrared spectra for (a) Iron oxide nanoparticles (Fe3O4 NPs), b Carboxymethyl chitosan, c Genistein, d Chitosan coated
iron oxide nanoparticles, e Genistein conjugated Fe3O4-CMC nanoparticles
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40 μmol/L genistein, 20 and 40 μmol/L nano-conjugated
Fe3O4-CMC-genistein and 40 μmol/L Fe3O4-CMC nano-
particles as compared to non-treated JURKAT cell lines.
The FACS analysis showed an increase in the percent-
age of early apoptotic cells from 5.1 to 11.2% for dose of
20 and 40 μmol/L of treated cells with only genistein,
but 20.5 and 21.5% cells were on early apoptotic stages
in effect of 48 h treatment with 20 and 40 μmol/L nano-
conjugated Fe3O4-CMC-genistein (Fig. 10). Significant
difference of early apoptotic cells was observed between
10 and 20 μmol/L of nano-conjugated Fe3O4-CMC-ge-
nistein and 20 and 40 μmol/L of only genistein (p =
0.012). No significant increase was observed in apoptosis
of cells treated with 40 μmol/L nano-particles contained
only Fe3O4-CMC in comparison with non-treated cells
(p = 0.114). Also, no significant difference in percentage
of early apoptotic cells was observed in 24 h and 48 h
treatment with nano-conjugated Fe3O4-CMC-genistein
(p = 0.064) as well as 20 and 40 μmol/L treatment (p =
0.079).
Discussion
The synthesizing procedure designed for conjugation of
genistein to iron oxide nanoparticles coated with bio-
compatible cross-linked chitosan, which is schematically
illustrated in Fig. 1. Carboxic groups existed in carboxy-
methylated chitosan (CMC) supply active sites for bind-
ing genistein and increase water-solubility of
nanoparticles [12]. EDC provide condensation circum-
stance for reaction carboxyl groups with –OH or –NH2
groups. In fact, EDC activated carboxyl group of CMC
to form an intermediate reactive ester, which covalently
react with -OH groups on the Fe3O4 nanoparticles to
decorate superparamagnetic nanoparticles with CMC,
and also “induce cross-linking between chitosan” [12,
27]. Then, genistein was attached to Fe3O4-CMC nano-
particles in circumstance provided by EDC condensation
reaction to achieve final Fe3O4-CMC-genistein nano-
conjugation for drug delivery system.
Obtained data from transmission electron microscopy
(TEM) showed that spherical shape of Fe3O4 and Fe3O4-
CMC-genistein nanoparticles with distance from each
other indicated their good water solubility [12]. Also,
iron oxide MNPs tend to aggregate due to their
magnetization effect, high surface energy and high
Fig. 6 Hysteresis loop for (a) Iron oxide nanoparticles (Fe3O4 NPs), (b) Genistein conjugated Fe3O4-CMC nanoparticles
Fig. 7 Separation of magnetic nanoparticles under an external
magnetic field
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surface area [28]. A mean diameter around 12ƞm also
confirmed proper synthesis of these particles. By com-
pare the X-ray diffraction of three nanoparticles of
naked iron oxide, Fe3O4-CMC and Fe3O4-CMC-genis-
tein showed that the surface functionalization did not
cause any phase change to the Fe3O4 nanoparticles and
Fig. 8 Cell growth assay of JURKET in the effect of 20 and 40 μmol/L genistein as well as 20 and 40 μmol/L Fe3O4-CMC-genistein as compared to
non-treated cells as well as treated cells with 40 μmol/L only Fe3O4-CMC nano-particles
Fig. 9 Proliferating assay of JURKET cells after treating by genistein & nano-conjugated genistein in different concentration 10, 20, 40, 80 μmol/L
during 24, 48 and 72 h. Results stated in percentage change in comparison with the zero concentration of genistein. * indicates p < 0.05 and **
refers to p < 0.005
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the crystal structures of samples are the same. The ob-
tained data from fourier transform infrared spectroscopy
(FTIR) confirmed that not only NPs surface is covered
with hydroxyl groups but also genistein successfully con-
jugated onto the Fe3O4-CMC nanoparticles.
In the other hand, the high amount of saturation
magnetization of naked Fe3O4 MNPs, although is
smaller than the bulk Iron oxide (around 92 emu/g), in-
dicate the good crystal structure [28]. The saturation
magnetization of Fe3O4-CMC-genistein NPs was smaller
than the value for the naked Fe3O4. The reduction of
saturation magnetization showed that the Fe3O4 MNPs
are surrounded by organic materials [29]. Decrease of
the mass saturation magnetization in the component
maybe due to the surface functionalization, which
caused the linkage between CMC and genistein onto the
surface of Fe3O4 nanoparticles [30]. Our synthesized
nano-particles incorporated in the composite particles
also demonstrated no remanence effect from the hyster-
esis loops when magnetic field applies.
The anti-cancer activity of synthesized Fe3O4-CMC-
genistein is dose- and time-dependent. These observa-
tions were also reported by other researchers such as
Wang et al., (2006) [31] and Choi et al., (2007) [32]. It
could be directed to a slow release of genistein from the
nano-conjugated Fe3O4-CMC-genistein. As the genistein
molecules were bounded covalently to the Fe3O4 nano-
particles, the prohibition effect might be weak at once.
The ester bond between genistein and the carboxy-
methyl chitosan could be hydrolyzed and genistein
started to release increasingly, resulted to augment pro-
hibit effect by passing the time. This result was similar
with observations of Si et al., (2010) on gastric cancer
cell line [12].
Fig. 10 The impact of 48 h treatment with different dose of Genistein on Apoptosis of JURKET cell line obtained by Flow Cytometry (The Flow
Cytometry charts supply in supplementary file)
Ghasemi Goorbandi et al. Biomaterials Research            (2020) 24:9 Page 11 of 13
Annexin based FACS analysis shows rate of apoptosis
and MTT assay indicate cell proliferation. Induction of
apoptosis is one of major mechanism for growth inhib-
ition of hematopoietic cancer cell lines by nano-
conjugated Fe3O4-CMC-genistein in lower dose. Induc-
tion of early apoptosis by free drug was distinctly lower
than nano-particles. In collation of obtained data by
FACS analysis and MTT assay, it deduced that genistein
can induce its anticancer effect by inhibition of prolifera-
tion and induce of apoptosis. It was also found that ge-
nistein in form of this synthesized nano-particle induce
its effect continuously, long lasting and more effective
for two times in lower dose for half.
Conclusions
In this study, we examined the effect of iron oxide
MNPs in combination with genistein for increasing its
anticancer effects. We have prepared a drug delivery sys-
tem for genistein using iron oxide MNPs and CMC. A
suitable polymer for coating iron oxide MNPs is CMC
due to its potential to create links between Fe3O4 NPs
and genistein. Another prominent characteristic for
CMC is its water solubility. The covalent binding be-
tween Fe3O4-CMC NPs and genistein leads to design
such a biocompatible drug delivery vehicle. By using
EDC as a strong cross linker, these bindings can be
formed. The results were confirmed by using TEM, DLS,
FTIR, XRD and VSM analysis. The analysis showed that
the size of nanoparticles increases after coating with
CMC and linking with genistein whereas in each step by
increasing the size of particles, the magnetic properties
decrease, which indicates proper binding with CMC and
genistein.
MTT assay and annexin-based FACS flow cytome-
try was used for determination of the effectiveness of
binding genistein in this drug delivery system. This
assay shows that the genistein was slowly released
from the Fe3O4-CMC-genistein drug delivery system
to hematopoietic cancer cells and its effect will prob-
ably long-last and pushed the cancer cells toward
apoptosis. The synthesized Fe3O4-CMC-genistein
nano-conjugated cause to empower its anti-cancer
activity in lower dose. This can probably improve its
chemotherapeutic features because of reduction of its
toxicity and increase of effectiveness in lower dose.
Fe3O4-CMC-genistein drug delivery system could be
considered as promising and futuristic carrier for
natural compounds with anticancer effect such as ge-
nistein. Since very few drug carriers included both
chitosan and magnetic nanoparticles have been re-
ported, particularly on genistein, hence further study
is necessity on other cancer cell lines as well as ani-
mal models.
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